Literature DB >> 15251944

Transrenal DNA as a diagnostic tool: important technical notes.

Ying-Hsiu Su1, Mengjun Wang, Timothy M Block, Olfert Landt, Irina Botezatu, Ol'ga Serdyuk, Anatoly Lichtenstein, Hovsep Melkonyan, L David Tomei, Samuil Umansky.   

Abstract

A small portion of DNA from apoptotic cells escapes complete degradation, appears in blood as oligonucleosomal-size fragments, is excreted in the urine, and can be used for diagnostic purposes. More detailed study revealed that transrenal DNA (Tr-DNA) belongs to a relatively low molecular-weight (150-250 bp) fraction, thereby requiring more careful attention to methods employed for purification and analysis. For example, here it is demonstrated that the QIAamp blood kit purifies primarily high molecular-weight DNA from serum, whereas the Guanidine/Promega Wizard Resin (GITC/WR) method purifies primarily low molecular-weight DNA. As a result, sensitivity in detection of K-RAS mutations in serum of patients with colorectal tumors is significantly higher with DNA isolated with the GITC/WR method than with the QIAamp kit. Amplicon size is also extremely important in analysis of Tr-DNA, because the shorter the amplicon, the higher is the sensitivity of biomarker detection in Tr-DNA. One hundred fifty-seven and 87 bp amplicons were employed for detection of mutant K-RAS in DNA isolated from 0.1 mL of urine obtained from 15 patients with pancreatic cancer. Mutant K-RAS was found in Tr-DNA of 3 and 10 patients with the long and short amplicons, respectively. The sensitivity and specificity of detection of mutant sequences are reduced in the presence of high excess of a respective wild-type allele, but they can be significantly increased through application of enriched polymerase chain reaction (PCR), peptide nucleic acid (PNA) clamped PCR, and/or stencil-aided mutation analysis (SAMA), based on selective pre-PCR elimination of wild-type sequences.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15251944     DOI: 10.1196/annals.1318.014

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  22 in total

1.  DNA hybridization detection with 100 zM sensitivity using piezoelectric plate sensors with an improved noise-reduction algorithm.

Authors:  Ceyhun E Kirimli; Wei-Heng Shih; Wan Y Shih
Journal:  Analyst       Date:  2014-06-07       Impact factor: 4.616

2.  Amplification-free in situ KRAS point mutation detection at 60 copies per mL in urine in a background of 1000-fold wild type.

Authors:  Ceyhun E Kirimli; Wei-Heng Shih; Wan Y Shih
Journal:  Analyst       Date:  2016-02-21       Impact factor: 4.616

3.  Differential methylation of the promoter and first exon of the RASSF1A gene in hepatocarcinogenesis.

Authors:  Surbhi Jain; Lijia Xie; Batbold Boldbaatar; Selena Y Lin; James P Hamilton; Stephen J Meltzer; Shun-Hua Chen; Chi-Tan Hu; Timothy M Block; Wei Song; Ying-Hsiu Su
Journal:  Hepatol Res       Date:  2014-12-09       Impact factor: 4.288

4.  Ultraspecific and Amplification-Free Quantification of Mutant DNA by Single-Molecule Kinetic Fingerprinting.

Authors:  Stephen L Hayward; Paul E Lund; Qing Kang; Alexander Johnson-Buck; Muneesh Tewari; Nils G Walter
Journal:  J Am Chem Soc       Date:  2018-09-05       Impact factor: 15.419

Review 5.  Urine-Based Liquid Biopsy for Nonurological Cancers.

Authors:  Surbhi Jain; Selena Y Lin; Wei Song; Ying-Hsiu Su
Journal:  Genet Test Mol Biomarkers       Date:  2019-04

6.  Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma.

Authors:  Hie-Won Hann; Surbhi Jain; Grace Park; Jamin D Steffen; Wei Song; Ying-Hsiu Su
Journal:  Hepatoma Res       Date:  2017-06-06

Review 7.  Clinical applications of urinary cell-free DNA in cancer: current insights and promising future.

Authors:  Tian Lu; Jinming Li
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

Review 8.  DNA markers in molecular diagnostics for hepatocellular carcinoma.

Authors:  Ying-Hsiu Su; Selena Y Lin; Wei Song; Surbhi Jain
Journal:  Expert Rev Mol Diagn       Date:  2014-08-07       Impact factor: 5.225

9.  DNA methylation in circulating tumour DNA as a biomarker for cancer.

Authors:  Ruth E Board; Lucy Knight; Alastair Greystoke; Fiona H Blackhall; Andrew Hughes; Caroline Dive; Malcolm Ranson
Journal:  Biomark Insights       Date:  2008-01-25

10.  Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps.

Authors:  Ying-Hsiu Su; Mengjun Wang; Dean E Brenner; Pamela A Norton; Timothy M Block
Journal:  Ann N Y Acad Sci       Date:  2008-08       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.